Dextromethorphan/bupropion

Dextromethorphan/bupropion
Dextromethorphan
Bupropion
Combination of
DextromethorphanNMDA receptor antagonist, σ1 receptor agonist, serotonin-norepinephrine reuptake inhibitor, nicotinic acetylcholine receptor negative allosteric modulator, and other actions
BupropionNorepinephrine–dopamine reuptake inhibitor and nicotinic acetylcholine receptor negative allosteric modulator
Clinical data
Trade namesAuvelity
Other namesDXM/BUP; AXS-05
License data
Routes of
administration		By mouth
ATC code
Legal status
Legal status
Identifiers
CAS Number
KEGG

Dextromethorphan/bupropion (DXM/BUP), sold under the brand name Auvelity, is a combination medication for the treatment of major depressive disorder (MDD).[1] Its active components are dextromethorphan (DXM) and bupropion.[1] Patients who stayed on the medication had an average of 11% greater reduction in depressive symptoms than placebo in an FDA approval trial.[2][3] It is taken as a tablet by mouth.[1]

Side effects of dextromethorphan/bupropion include dizziness, headache, diarrhea, somnolence, dry mouth, sexual dysfunction, and hyperhidrosis, among others.[1] The mechanism of action of dextromethorphan/bupropion in the treatment of depression is unknown.[1]

Dextromethorphan/bupropion was developed by Axsome Therapeutics and was approved for the treatment of major depressive disorder in the United States in August 2022.[1]

  1. ^ a b c d e f g "Auvelity- dextromethorphan hydrobromide, bupropion hydrochloride tablet, multilayer, extended release". DailyMed. 15 December 2022. Retrieved 21 January 2023.
  2. ^ Cite error: The named reference Auvelity FDA Label was invoked but never defined (see the help page).
  3. ^ Cite error: The named reference pmid35649167 was invoked but never defined (see the help page).
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.